Waiting list

26 March 10:00Operaterrassen

Welcome to Flerie’s Biotech Innovation Day

We are pleased to invite you to an exclusive event at Operaterrassen in Stockholm, Sweden on March 26, 2026, featuring presentations from Flerie’s portfolio companies and a panel discussion with leading decision‑makers from global pharma alongside representatives from leading financial institution.

This event provides private and institutional investors, as well as industry executives, strategic updates, insights into a selection of Flerie’s portfolio companies, and the opportunity to engage directly with key leaders shaping the future of life science.

We look forward to welcoming you to this insightful and engaging event.

Waiting list

Agenda

10:00

Welcoming Remarks


Read more
Dr. Ted Fjällman, CEO
Flerie
10:05

Portfolio Company Presentations

Select CEOs from Flerie’s portfolio companies will highlight their innovations and growth potential.

Read more
Dr. Livija Deban, CSO
Prokarium
Ola Sandborgh, CEO
Lipum
Dr. Charlotte Fribert, CEO
Bonsai Biotherapeutics
Maria Bech, CEO
EpiEndo Pharmaceuticals
Dr. Patrik Strömberg, CEO
AnaCardio
11:45

Executive Panel: Global Pharma Outlook

A high‑level discussion featuring decision‑makers from global pharmaceutical companies alongside representatives from leading financial institutions, moderated by Jenni Nordborg. The panel will explore current industry dynamics, partnership trends, and the evolving biotech–pharma landscape.

Read more
Dr. Jenni Nordborg
Board of Directors Flerie and Director of Strategy and Public Affairs at LIF
12:15

Paus

A short break with the opportunity to network and connect with fellow attendees.

Read more
12:30

Networking Lunch

A chance to continue discussions and connect with speakers, investors, and industry leaders in an informal setting.

Read more
14:00

Mingle

Biotech Innovation Day

The event will be held at Operaterrassen in Stockholm on March 26, 2026. Select CEOs from Flerie’s portfolio companies will highlight their innovations and growth potential. In addition, there will be a panel discussion with leading decision‑makers from global pharma, moderated by Jenni Nordborg.

We invite all event participants to join us for lunch at Operaterrassen at 12:30 CEST. Please confirm your attendance at your earliest convenience.

Annual General Meeting
The event will be held in conjunction with the Annual General Meeting of Flerie AB. Shareholders who wish to attend the Annual General Meeting must register in accordance with the notification to attend the AGM.  

Link to the notification to attend the AGM: Annual General Meeting 2026 – Flerie


Waiting list
© MapTiler © OpenStreetMap contributors

Speakers

Dr. Ted Fjällman, CEO
Flerie

Flerie

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Read more

Dr. Patrik Strömberg, CEO
AnaCardio

AnaCardio

Novel drugs developed to address an underlying problem in heart failure, decreased contractility, based on innovative research from the Karolinska Institute. 

Heart failure is a progressive cardiac syndrome that hinders the ventricles’ ability to fill with or pump blood. This condition impacts nearly 100 million people globally, leading to poor quality of life, frequent hospitalisations, and high risk of mortality. Today’s oral therapies can slow progression and decrease hospitalisations and mortality, but no treatment on the market addresses the root cause of impaired contractility in a safe manner. 

AnaCardio is developing novel inotropic agents with a unique mode of action based on the ghrelin signaling pathway. Unlike current therapies, AnaCardio’s treatment enhances cardiomyocyte contractility and force, thereby increasing cardiac output and potentially improving organ function. This may lead to greater functional capacity, quality of life, and reduced risk of hospitalisation and mortality. AnaCardio’s treatment concept arises from groundbreaking research from the Karolinska Institute and Professor Lars Lund, the company’s founder. 

AnaCardio is a privately held company based in Stockholm, Sweden.

Read more

Dr. Charlotte Fribert, CEO
Bonsai Biotherapeutics

Bonsai Biotherapeutics

Biological treatments that restore the normal function of the immune system and potentially cure patients of serious autoimmune diseases, starting with myasthenia gravis. Autoimmune diseases arise when the immune system incorrectly attacks the body’s own tissue. In myasthenia gravis (MG), the immune system recognises key proteins as foreign and initiates an ‘attack’ on receptors required for nerve conduction to muscle, leading to progressive weakness. To date, there are no cures for this debilitating disease, and available treatments often have limited effects, causing impediments to day-to-day activities.

Bonsai Biotherapeutics is developing breakthrough drug candidates that restore the immune system’s tolerance to the proteins mistakenly attacked in MG and ANCA vasculitis. The drug candidates consist of modified versions of the targeted proteins produced in a biological manufacturing process. The company’s most advanced therapeutic candidate, TOL2 for myasthenia gravis, is expected to enter a placebo-controlled clinical trial in MG patients in 2026.

Bonsai Biotherapeutics is a privately held company based in Gothenburg, Sweden.

Read more

Maria Bech, CEO
EpiEndo Pharmaceuticals

EpiEndo Pharmaceuticals

First-in-class oral anti-inflammatory drug for chronic respiratory diseases. 

Chronic obstructive pulmonary disease (COPD) is a progressive lung condition characterised by persistent respiratory symptoms and restricted airflow. A key feature of the disease is exacerbations that can be either infective or non-infective in nature, primarily triggered by viruses, bacteria, and airborne irritants. COPD affects around 390 million people worldwide and is the third leading cause of death worldwide.

EpiEndo Pharmaceuticals is developing a novel oral first-in-class therapeutic, glasmacinal (previously EP395), to reduce exacerbations of COPD. It is well known that one class of antibiotics (macrolides) has unique anti-iflammatory properties, in addition to its antimicrobial effects. EpiEndo harnesses this, removing the antibiotic properties that would otherwise increase the risk of antimicrobial resistance when used chronically, to develop a new class of anti-inflammatory drugs. Glasmacinal successfully completed a Phase 2a trial in 2024.

EpiEndo Pharmaceuticals is a privately held company based in Reykjavik, Iceland.

Read more

Ola Sandborgh, CEO
Lipum

Lipum

A biological drug candidate with a novel target shown to play a role in many inflammatory diseases, initially focusing on rheumatoid arthritis.

Autoimmune disorders occur when the immune system mistakenly attacks the body’s own cells or tissues, causing inflammation. Bile Salt-Stimulated Lipase (BSSL), a protein initially discovered in breast milk, plays a significant role in inflammation and is present in human granulocytes, a type of white blood cell essential for the body’s defence against pathogens. One condition where BSSL is thought to play an important role is rheumatoid arthritis, a chronic autoinflammatory disorder primarily affecting the joints.

Lipum is developing a biological anti-inflammatory drug candidate SOL-116 that features a novel mechanism of action targeting BSSL. The company is initially focused on treating rheumatoid arthritis while also exploring other inflammatory diseases with significant unmet medical needs, such as juvenile idiopathic arthritis and inflammatory bowel disease. Lipum has completed a Phase I clinical study assessing SOL-116 in healthy volunteers and a group of patients with rheumatoid arthritis.

Lipum is based in Umeå, Sweden, and was publicly listed until its merger with Flerie in
2026, after which it is privately held.

Read more

Dr. Livija Deban, CSO
Prokarium

Prokarium

A novel microbial immunotherapy for bladder cancer, based on a broadly applicable synthetic biology platform. 

Synthetic biology has emerged as a powerful approach in cancer research and treatment, with significant advancements and potential clinical applications on the horizon. The company has developed a microbial immunotherapy that can replace the current standard of care for non-muscle invasive bladder cancer (NMIBC) and can be expanded to muscleinvasive disease and other solid tumour indications based on a broad and strong patent portfolio. Bladder cancer is one of the costliest cancers to treat, representing 5% of all new cases in the US, of which 70% are diagnosed at the NMIBC stage.

Prokarium’s most advanced therapeutic agent ZH9 is a modified bacterium that acts as an immunotherapy currently being evaluated in a multicenter Phase I clinical trial in NMIBC patients in the US. The study initially aims to demonstrate safety, and if successful, advance to characterise the clinical efficacy of ZH9 in a pre-planned expansion cohort.

Prokarium is a privately held company based in London, the United Kingdom.

Read more

Dr. Jenni Nordborg
Board of Directors Flerie and Director of Strategy and Public Affairs at LIF


Executive Director for Strategy and Public Affairs at Lif - The Research-Based Pharmaceutical Industry in Sweden. Dr. Nordborg is a strategic executive and with long-term experience in life sciences policy making on national and international level. Dr. Nordborg is the former National Life Sciences Coordinator, established and headed the Office for Life Sciences at the Government Offices of Sweden and was responsible for the first Swedish National Life Sciences Strategy. Dr. Nordborg has previously been Director and Head of the Health Division at Vinnova, the Swedish Governmental Innovation Agency. Her research background is from Chalmers University of Technology. She is Board Member of Flerie and IHE - the Swedish Institute for Health Economics.

Read more

Fleriecontact@flerie.com